Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events reported included edema, nausea, diarrhea, myalgia or musculoskeletal pain, fatigue, dermatitis or rash, headache and abdominal pain. Hypophosphatemia is rare side effect of imatinib treatment. This is the report of a case experiencing severe hypophosphatemia during adjuvant treatment with imatinib for gastrointestinal stromal tumor.
Introduction
Imatinib mesylate is a 2-phenylaminopyrimidine derivative that binds to the adenosine triphosphate (ATP)ebinding site of a select group of protein tyrosine kinases, thereby precluding ATP-binding and inhibiting kinase activity. 1 Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. 2, 3 It is currently the "gold standard" treatment for Philadelphia chromosomee positive chronic myeloid leukemia (CML) in chronic phase and for gastrointestinal stromal tumors (GISTs). Imatinib is generally well tolerated; most side effects are less than grade 2, and the majority of patients can continue treatment without interruption. In general, the side effect profile tends to improve with prolonged therapy. 4 The most common side effects reported in patients receiving imatinib are fluid retention, diarrhea, nausea, fatigue, muscle cramps, abdominal pain, and rash. Altered phosphate metabolism was first reported in patients receiving imatinib therapy for GIST, CML, and sarcoma by Berman et al. 5 Hypophosphatemia is reported, especially with higher doses. 6 The reported prevalence of hypophosphatemia varies widely, depending upon the patient population surveyed and the concentration of serum phosphorus used to define hypophosphatemia. Up to 5% of hospitalized patients may have low serum phosphate concentrations (less than 2.5 mg/dl [0.80 mmol/L]), although prevalences of over 30 to 50% have been reported in alcoholic patients and patients with severe sepsis or trauma. 7, 8 Serum phosphate or phosphorus normally ranges from 2.5 to 4.5 mg/dl (0.81e1.45 mmol/l) in adults. Hypophosphatemia is defined as mild (2e2.5 mg/dl or 0.65e0.81 mmol/l), moderate (1e2 mg/dl or 0.32e0.65 mmol/l), or severe (<1 mg/dl or 0.32 mmol/l). 9 There are four major mechanisms by which hypophosphatemia can occur (Table 1) . Medication, particularly molecular-targeted agents, might induce hypophosphatemia ( Table 2) . Hypophosphatemia is also associated with cancer and is called oncogenous osteomalacia.
We reported that hypophosphatemia developed in patient with newly diagnosed GIST who had adjuvant imatinib therapy.
Case report
A 36-year-old female presented with abdominal pain and diarrhea since 4 months. There was no pathological finding on physical examination. The routine hematological and biochemical examinations were within normal limits. A hypoechoic lesion (5 Â 3.3 cm) was detected on the inferior head of pancreas, in abdominal ultrasonography (USG). This lesion was also detected (43 Â 31 mm) in fourth part of duodenum on abdominal computerized tomography (CT). Biopsy was performed on the patient with endoultrasonography. Biopsy was reported as GIST. Dog-1,SMA,CD-117 was positive in the pathology report. Small intestine resection was performed. Tumor was located in duodenum, diameter was 3.5 cm, mitosis was <5, surgical margin was positive for GIST in microscopic examination. Re-operation was not considered. Patient was considered at high risk for recurrence. Imatinib (400 mg/day) therapy was started. Nausea, fatigue, weakness (grade-2) and muscle cramps was seen 2 months after the start of treatment. Intoleration evolved into drug use. Hypophosphatemia was detected in biochemical test (P: 0.6 mg/dl (grade-4)). In previous tests before starting treatment with imatinib, normal phosphorus levels (3.2 mg/dl) was observed. There is no any etiologic factor that may cause hypophosphatemia for this patient. Imatinib therapy was continued. Phosphorus replacement therapy was performed. Despite the replacement therapy phosphorus level was 0.4 mg/dl (grade 4) measured (Table 3) . Parathyroid hormone (PTH) level was detected 125 pg/ml and 25 hydroxy vitamin-D3 (25-OH-VitD) level was detected 24,7 ng/ml. And then calcitriol therapy was added the phosphorus replacement therapy. 1 months later PTH: 50 pg/ml, 25-OH-VitD:38 ng/ml, P: 2.4 mg/dl was measured. The patient's weakness, fatigue, nausea, muscle cramps resolved completely with replacement therapy. PTH: 27 pg/ml, 25-OH-VitD:53 ng/ml, P: 3.2 mg/dl was measured in the last biochemical tests. Calcium levels were always at normal levels. Now the patient continues to imatinib (400 mg/day) without any complaints (see Figs. 1e3 ).
Discussion
Imatinib has been well tolerated in clinical studies with adverse events typically mild to moderate in nature, usually managed without permanent discontinuation of therapy. In general, the side effect profile of imatinib tends to improve with prolonged therapy. In the first report of imatinib efficacy and safety in advanced GIST, treatment with imatinib was well tolerated, although virtually almost every patient (98%) had at least a grade 1 or 2 adverse event that might have been related to therapy. The most common adverse events reported included edema (most frequently periorbital), nausea, diarrhea, myalgia or musculoskeletal pain, fatigue, dermatitis or rash, headache and abdominal pain. Serious adverse events (grade 3 or 4) in that trial occurred in 21% of patients of which the most serious adverse events reported were gastrointestinal or intraabdominal hemorrhages. 10 Doubling the dosage of imatinib from the standard level (400 mg daily) to a high dose (400 mg twice daily) increases the incidence of severe adverse events. 11 No correlation could be seen between imatinib plasma level and previous grade 3 to 4 toxicity in patients taken a standard dose of 400 mg daily. 12 Hypophosphatemia was reported as a rare side effect of imatinib during initial trials. Berman et al. described bone-remodeling occurring in 16 patients treated with imatinib in 2006. In this study, hypophosphatemia and a series of associated changes in bone and mineral metabolism occurred in some patients receiving imatinib for either CML or gastrointestinal stromal tumors. They found PTH levels were high in the low-phosphate group. This finding strongly suggests that parathyroid function is in fact abnormal in this group. Imatinib inhibits tyrosine kinases associated with specific diseases, their data suggest that in vivo inhibition of the PDGF receptor may also occur and may have clinical consequences. They adviced routine monitoring of serum phosphate and vitamin D level during imatinib therapy. 5 Oncogenic osteomalacia is an unusual syndrome that is characterized by multiple biochemical abnormalities, such as hypophosphatemia, hyperphosphaturia, and low levels of plasma 1,25-dihydroxyvitamin D. These abnormalities produce osteomalacia in adults and rickets in children, which clinically manifest as muscle weakness, bone pain, and multiple pathologic fractures. Tumors producing this syndrome secrete a substance that inhibits the renal tubular reabsorption of phosphates, which produces a cascade of biochemical abnormalities. 13 Tumors that cause Removal by renal replacement therapies Table 2 Etiology of drug-induced hypophosphatemia. Oncogenic osteomacia are often small, slow-growing, vascular, and benign; they are associated with a variety of histologic types and are commonly mesenchymal in origin.
14 Unexplained generalized bone pain or multiple fractures must be tested for calcium and phosphate homeostasis for a complete diagnostic work-up. The pathogenesis of the hypophosphatemia is not understood. Imatinib inhibits of osteoclasts, by blocking c-fms, c-kit, and PDGFR signaling, and inhibits activation of osteoblast activity through inhibition of PDGFR. Inhibition of bone remodeling may because decreased bone formation and bone resorption. The amount of calcium and phosphorus released from the bone to the extracellular space is decreasing. And then PTH increasing as a compensator. Renal phosphorus excretion is increasing. 5 In our case, hypophosphatemia developed two months later after starting imatinib treatment. Nausea, fatigue, weakness and muscle cramps have been observed with imatinib therapy. These symptoms were resolved after the treatment of hypophosphatemia. These symptoms are common side effects of imatinib treatment. Hypophosphatemia may develop quickly after imatinib treatment. Berman et al. Reported two patients who have low serum phosphate levels within two weeks after starting imatinib therapy. 5 For his reason, we recommend that routine monitoring of serum 
